SR3335

293753-05-6

C13H9F6NO3S2

DMSO : >= 100 mg/mL (246.71 mM)

Metabolic Enzyme/Protease

SR3335 is a selective RORalpha synthetic ligand, directly binds to RORalpha (K_i 220 nM) but not other RORs, and functions as a selective partial inverse agonist of RORalpha in cell-based assays. IC50 & Target: Ki: 220 nM (RORalpha)^[1] In Vitro: SR3335 is a selective RORalpha partial inverse agonist. In a biochemical radioligand binding assay using [³H]25-hydroxycholesterol as a label it is clear that unlabeled SR3335 dose-dependently competes for binding to the RORalpha LBD. The K_i is calculated as 220 nM using the Cheng-Prusoff equation. In a cell-based chimeric receptor Gal4 DNA-binding domain-NR ligand binding domain cotransfection assay, SR3335 significantly inhibits the constitutive transactivation activity of RORalpha (IC₅₀=480 nM)(partial inverse agonist activity), but has no effect on the activity of LXRalpha and RORgamma^[1]. In Vivo: Pharmacokinetic studies indicate that SR3335 displays reasonable exposure following an i.p. injection into mice. The ability of SR3335 is assessed to suppress gluconeogenesis using a diet induced obesity (DIO) mouse model where the mice where treated with 15 mg/kg b.i.d., i.p. for 6-days followed by a pyruvate tolerance test. SR3335 treated mice displays lower plasma glucose levels following the pyruvate challenge consistent with suppression of gluconeogenesis. Importantly, mice treated with SR3335 displayed no difference in body weight or food intake after 7-days of treatment with SR3335^[1].